Financial Results for the First Quarter of
Fiscal Year Ending March 31, 2023 (FY2022)

from the beginning

Financial Results for the First Quarter of Fiscal Year Ending March 31, 2023 (FY2022)

• Safe Harbor for Forward-Looking Statements and Use of Document

• FY22 Q1 Results Highlights

• P&L Results

• Operating Profit Variance Analysis

• Revenue by Region

• C&V: Number of procedures moved from recovery to growth trend in all regions but Japan, with all businesses growing sales. Segment profit returned to normal levels as business activities resumed

• TMCS: Drivers were general hospital product growth in North America and Pharmaceutical Solutions sales increase, resulting in sales growth. Segment profit decreased due to FX impact and resumption of business activities

• TBCT: Automation innovation and demand recovery contributed to large growth in whole blood market. Plasma Innovation expenses and resumption of activities, resulting in slowing of segment profit

• Product Pipeline and Major Topics

Reference

• Revenue by Segment and Region

• Quarterly Trend of Revenue and Operating Profit

• Quarterly Results

• Operating Expenses (Quarterly Trend)

• Operating Expenses (Quarterly Results)

• Adjusted Operating Profit amount

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (Q1)

• FY22 FX Impact Breakdown (Flow, Stock)

• Foreign Exchange Sensitivity

@